A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 19, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Healthy

Interventions

DRUG

LY4292009

Administered orally

DRUG

Placebo

Administered orally.

Trial Locations (1)

RECRUITING

Altasciences Company Inc., Mount Royal

All Listed Sponsors

lead

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

INDUSTRY